Now the aspirin response signature can resolve who is at the peril of heart attack and death.

Scientists at Duke Medicine have found that a genomic signature in blood regulates the response of patients to aspirin.
The test of gene activity conducted by the researchers identified the fact that the resistance to aspirin by some patients was due to the genetic make-up of their cardiovascular system. Scientists revealed with accuracy which patients will respond to aspirin therapy.
This new gene based blood test calculates the efficiency of aspirin and gives factual analysis of the patients at risk for heart attack or stroke.
The experiments were conducted on three teams of participants. Scientists formed two teams of healthy people and one team of cardiology heart outpatients.
A dosage of 325 mg of aspirin was administered daily for a month to the Healthy people. The cardiology outpatients were given a low dosage of aspirin. After that blood samples were tested for the effect of aspirin on RNA expression and the activity of platelets in clotting of blood.
After intake of Aspirin, the RNA micro array identified a set of 60 co-expressed genes named by the scientists as the aspirin response signature.
Geoffrey S. Ginsburg, the director of genomic medicine at Duke’s Institute for Genome Sciences & Policy and executive director of the Center for Personalized Medicine said that there is aspirin resistance among patients suffering from cardiac diseases or stroke
These co-expressed gene sets constantly interrelated to an inadequate platelet response to aspirin therapy in both the healthy patients and the patients suffering from heart diseases. They conducted research on a group of heart patients who had undergone catheterization .It was found that the response signature was also successful in recognizing those patients who sooner or later had a heart attack or eventually died.
He added that the biology of platelets with a genomic signature in blood regulates the response of patients to aspirin.